578 related articles for article (PubMed ID: 26323992)
21. A case of immune reconstitution syndrome complicating progressive multifocal leukoencephalopathy after kidney transplant: Clinical, pathological, and radiographic features.
Jackowiak E; Shah N; Chen H; Ojha A; Doyle J; Shepler A; Bogdanovich T; Silveira FP; Haidar G
Transpl Infect Dis; 2019 Oct; 21(5):e13162. PubMed ID: 31419376
[TBL] [Abstract][Full Text] [Related]
22. Immunology of progressive multifocal leukoencephalopathy.
Jelcic I; Jelcic I; Faigle W; Sospedra M; Martin R
J Neurovirol; 2015 Dec; 21(6):614-22. PubMed ID: 25740538
[TBL] [Abstract][Full Text] [Related]
23. History and current concepts in the pathogenesis of PML.
Major EO
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S3-7. PubMed ID: 22123932
[TBL] [Abstract][Full Text] [Related]
24. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
25. Progressive multifocal leukoencephalopathy therapy.
Clifford DB
J Neurovirol; 2015 Dec; 21(6):632-6. PubMed ID: 25227934
[TBL] [Abstract][Full Text] [Related]
26. The spectrum of progressive multifocal leukoencephalopathy: a practical approach.
Bartsch T; Rempe T; Leypoldt F; Riedel C; Jansen O; Berg D; Deuschl G
Eur J Neurol; 2019 Apr; 26(4):566-e41. PubMed ID: 30629326
[TBL] [Abstract][Full Text] [Related]
27. Progressive multifocal leukoencephalopathy - immune reconstitution inflammatory syndrome (PML-IRIS) in liver transplant recipient.
Avsenik J; Horvat Ledinek A; Šurlan Popovič K
Mult Scler Relat Disord; 2017 Oct; 17():135-137. PubMed ID: 29055444
[TBL] [Abstract][Full Text] [Related]
28. Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy.
Harrison DM; Newsome SD; Skolasky RL; McArthur JC; Nath A
J Neuroimmunol; 2011 Sep; 238(1-2):81-6. PubMed ID: 21840066
[TBL] [Abstract][Full Text] [Related]
29. Advances in the management of PML: focus on natalizumab.
Fox R
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
[TBL] [Abstract][Full Text] [Related]
30. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
[TBL] [Abstract][Full Text] [Related]
31. Not a Disease of the Past: A Case Series of Progressive Multifocal Leukoencephalopathy in the Established Antiretroviral Era.
Summers NA; Kelley CF; Armstrong W; Marconi VC; Nguyen ML
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):544-552. PubMed ID: 30834775
[TBL] [Abstract][Full Text] [Related]
32. Radiological abnormalities in progressive multifocal leukoencephalopathy: Identifying typical and atypical imaging patterns for early diagnosis and differential considerations.
Soni N; Ora M; Mangla R; Singh R; Ellika S; Agarwal A; Meyers SP; Bathla G
Mult Scler Relat Disord; 2023 Sep; 77():104830. PubMed ID: 37418930
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppression increases JC polyomavirus large T antigen DNA load in the brains of patients without progressive multifocal leukoencephalopathy.
Bayliss J; Karasoulos T; McLean CA
J Infect Dis; 2013 Jan; 207(1):133-6. PubMed ID: 23112281
[TBL] [Abstract][Full Text] [Related]
34. Progressive multifocal leukoencephalopathy.
Aksamit AJ
Continuum (Minneap Minn); 2012 Dec; 18(6 Infectious Disease):1374-91. PubMed ID: 23221846
[TBL] [Abstract][Full Text] [Related]
35. Progressive multifocal leukoencephalopathy treated with nivolumab.
Hoang E; Bartlett NL; Goyal MS; Schmidt RE; Clifford DB
J Neurovirol; 2019 Apr; 25(2):284-287. PubMed ID: 30864100
[TBL] [Abstract][Full Text] [Related]
36. A Kidney Transplant Recipient With Fulminant Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome: A Rare Clinical Outcome and Review of the Literature.
Kirincich J; Basic-Jukic N; Radic J; Lovric-Kujundzic S; Kastelan Z
Exp Clin Transplant; 2020 Apr; 18(2):242-246. PubMed ID: 31580233
[TBL] [Abstract][Full Text] [Related]
37. Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
Jelcic I; Combaluzier B; Jelcic I; Faigle W; Senn L; Reinhart BJ; Ströh L; Nitsch RM; Stehle T; Sospedra M; Grimm J; Martin R
Sci Transl Med; 2015 Sep; 7(306):306ra150. PubMed ID: 26400911
[TBL] [Abstract][Full Text] [Related]
38. Progressive multifocal leukoencephalopathy: Dot-shaped inclusions and virus-host interactions.
Shishido-Hara Y
Neuropathology; 2015 Oct; 35(5):487-96. PubMed ID: 25946231
[TBL] [Abstract][Full Text] [Related]
39. Differences in T cell cytotoxicity and cell death mechanisms between progressive multifocal leukoencephalopathy, herpes simplex virus encephalitis and cytomegalovirus encephalitis.
Laukoter S; Rauschka H; Tröscher AR; Köck U; Saji E; Jellinger K; Lassmann H; Bauer J
Acta Neuropathol; 2017 Apr; 133(4):613-627. PubMed ID: 27817117
[TBL] [Abstract][Full Text] [Related]
40. Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
Tan LA; Lopes DK
J Clin Neurosci; 2015 Oct; 22(10):1669-71. PubMed ID: 26115897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
